NICE ends Prolia appraisal for prostate cancer

The U.K.'s NICE terminated an appraisal of Prolia denosumab to treat therapy-induced bone-loss in patients with non-metastatic prostate cancer because it did not receive an evidence submission from Amgen Inc. (NASDAQ:AMGN). According to NICE, Amgen told the agency it had decided to focus its resources elsewhere due to a high volume of upcoming NICE appraisals of Amgen's products. Without a NICE appraisal for the indication, the decision to recommend use of Prolia will be made by individual NHS organizations on a local level. ...